This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 193766 Submitted by lobbyist on: March 22, 2012 11:44:17 AM Accepted by Registrar on: March 26, 2012 11:18:43 AM
Designated Filer Information
Miller, Ronnie
2455 Meadowpine Blvd.
Mississagua,, ON, L5N 6L7
905-542-5555
Canada
Organization Information
Hoffmann-La Roche Limited
Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development including clinical research, clinical trials and genetic research.
2455 Meadowpine Blvd.
Mississagua,, ON, L5N 6L7
905-542-5667
Canada
Relevant Affiliates
Type:
Business Name
Mailing Address
Contact Information
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
Basle,
Switzerland
Phone:
9055425667
Government or Government Agency Funding
The organization does not receive any funding from a government or government agency.
Other Controlling or Directing Interests
The organization has no other controlling or directing interests.
Active Registration Period
March 22, 2012
October 26, 2012
Organization's In-House Lobbyists
Name:
Arora, Nita
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Biondi, Lorenzo
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Macdonald, Gene
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Miller, Ronnie
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Milliken, Debbie
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Nolet, Brigitte
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Oteman, Katia
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Pritchard, Gordon
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Siemers, Peter
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Torontali, Ilona
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
de Jong,
Mike
Minister of Health
March 22, 2012
Minister
Falcon,
Kevin
Minister of Finance
March 22, 2012
Name:
Wells, Brigitte
March 22, 2012
Inactivation Date:
November 30, 2012
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Annual Provincial Budgets and Budget updates as it relates to the biopharmaceutical industry. Biologics and Genetic Therapies as it relates to policy affecting the review, approval adn process of submissions. PTF Recommendations.Creation of pathways for Subsequent Entry Biologics (SEBs)regarding: information and submission requirements for SEBs, and provincial regulations and process for review. Pricing policy as it relates to the Biopharmaceutical industry in BC.Lobbying in regards to Policy and Market Access in the following areas: Pandemic Planning and Anti-Virals, Oncology, Rheumatology, Transplant, Urgent Care, Virology and Clinical Research.Lobbying regarding the general improvement of Biopharmaceutical business environment in BC.
